

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.

**This form may contain multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.**

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information (if any):		
Is the requested medication: <input type="checkbox"/> New or <input type="checkbox"/> Continuation of Therapy? If continuation, list start date: _____		
Is this patient currently hospitalized? <input type="checkbox"/> Yes <input type="checkbox"/> No If recently discharged, list discharge date: _____		

Section B - Provider Information

First Name:	Last Name:	M.D./D.O.	
Address:	City:	State:	ZIP code:
NPI #:	Phone:	Fax:	Specialty:
Office Contact Name / Fax attention to:			

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:
Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____	

Section D – Previous Medication Trials

Medication Name	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

**Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs:
Please refer to the patient's PDL for a list of preferred alternatives**

Member First name:	Member Last name:	Member DOB:
--------------------	-------------------	-------------

Clinical and Drug Specific Information

ALL REQUESTS:

- Is the patient currently on Siliq therapy? Yes No If yes, list start date: _____

- Does the patient have a diagnosis of chronic moderate to severe plaque psoriasis? Yes No
If no, list diagnosis: _____
(must submit medical documentation)

- Does the patient have greater than or equal to 5% body surface area involvement, palmoplantar, facial, or genital involvement, or severe scalp psoriasis? Yes No *(must submit medical documentation)*

- Does the patient have a history of failure, contraindication, or intolerance to one of the following topical therapies (Corticosteroids (e.g., betamethasone, clobetasol, desonide), Vitamin D analogs (e.g., calcitriol, calcipotriene), Tazarotene, Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus), Anthralin, Coal tar)? Yes No
(If yes, complete Section D above with medication information, including dose, date of trial, and reason for discontinuation)
(must submit medical documentation)

- Does the patient have a history of failure, contraindication, or intolerance to systemic therapy of at least **3 months** duration with methotrexate? Yes No *(must submit medical documentation)*
(If yes, complete Section D above with medication information, including dose, date of trial, and reason for discontinuation)

- Does the patient have a history of failure, contraindication, or intolerance to Humira (adalimumab) and/or Enbrel (etanercept)? Yes No *(must submit medical documentation)*
(If yes, complete Section D above with medication information, including dose, date of trial, and reason for discontinuation)

- Will the patient receive Siliq in combination with any of the following: Yes No (check which apply)
 - Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Cosentyx (secukinumab), Orencia (abatacept)]
 - Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
 - Phosphodiesterase 4 (PDE4) inhibitor [e.g. Otezla (apremilast)]

Requests for CONTINUATION OF THERAPY:

- Does the patient have a documented positive clinical response to Siliq therapy? Yes No
If yes, list response: _____

Provider Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.